Stocktoria
Lyra Therapeutics, Inc. LYRA
OTC · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2020-05-01
Lyra Therapeutics, Inc. financials (annual, from 10-K)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $398,000 | $1.5M | $1.6M | $1.4M | $285,000 | — | — |
| R&D expense | $18.4M | $43.8M | $48.0M | $38.8M | $29.7M | $12.5M | $12.0M |
| Operating income | -$31.0M | -$96.3M | -$67.1M | -$56.3M | -$43.6M | -$22.2M | -$16.5M |
| Income tax | $11,000 | $39,000 | $59,000 | $13,000 | $0 | $0 | $0 |
| Net income | -$28.9M | -$93.4M | -$62.7M | -$55.3M | -$43.5M | -$22.1M | -$16.3M |
| EPS (diluted) | $-18.62 | $-71.75 | $-1.26 | $-1.83 | $-3.35 | — | — |
| Operating cash flow | -$28.9M | -$70.0M | -$63.3M | -$43.4M | -$25.8M | -$21.1M | -$13.8M |
| Free cash flow | -$29.0M | -$72.3M | -$64.4M | -$43.5M | -$29.2M | -$22.9M | -$14.0M |
| Cash & equivalents | $15.9M | $40.6M | $22.4M | $32.5M | $45.7M | $74.6M | $9.8M |
| Total assets | $36.1M | $66.3M | $142.6M | $110.0M | $54.9M | $80.8M | $15.0M |
| Total liabilities | $46.8M | $54.8M | $53.2M | $29.2M | $20.6M | $6.3M | $7.6M |
| Shareholders' equity | -$10.7M | $11.6M | $89.4M | $80.8M | $34.3M | $74.5M | -$123.3M |
Growth · year-over-year · Revenue CAGR 8.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | -74.1% | -1.5% | +14.3% | +378.2% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001327273 · US · as of 2025-12-31. facts plus Stocktoria's own computed scores — not investment advice.